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and balance, and may also cause memory improvement in
some patients.
Osteoporosis is a major problem in post-menopausal
women. Stavros Manolagas explains that bone marrow cells
possess classical oestrogen receptors; both androgens and
oestrogens suppress interleukin 6 (IL-6) and, after oestrogen
is reduced, the increase in IL-6 causes an increase in
osteoclast production. Conversely, IL-6 suppression de-
creases bone loss.
Women suffer disproportionately from autoimmune
diseases, and Howard Fox explains that androgens and
oestrogens are probably the major determinants of this
phenomenon. In rats, androgen was necessary to maintain
low levels of autoantibodies, and treatment with androgens
prevents diabetes. The sex hormones act by altering gene
expression; oestrogen treatment positively regulated the
gamma-interferon promoter.
Many breast tumours are hormone responsive in the sense
that they are dependent on oestrogen for their growth and
development. Oestrogen deprivation is still the keystone of
treatment. However, sooner or later tumour cells lose their
hormone dependence and escape therapeutic control. Kate
Horwitz suggests that this is because the cells have altered
responsiveness through changes in the regulatory mechan-
isms; this may be due to activation ofinhibitors by oestrogen
metabolites. Progesterone receptors exist in two functionally
different (inhibitory and activatory) forms that interact. In
discussion, it was accepted that translation of experimental
data to in vivo models is difficult but all these experiments
offered an insight into specific aspects of oestrogen action in
breast cancer.
Several oestrogen-induced proteins occur in oestrogen
receptor-positive cancers. Henri Rochefort explains that
some had prognostic significance, particularly pS2 and
cathepsin D, a lysosomal protease. Oestrogen also modulates
transcription of various genes, and the oestrogen receptor
and various transcription factors interact.
Prostate cancer is common in older men, and testosterone
is closely involved in the development and growth of these
tumours. Using prostate cancer cell lines in vitro, Luigi
Castagnetta had examined the role of oestradiol and showed
that some cell lines are inhibited in their growth by
oestradiol, whereas others are stimulated. This hormone
may act synergistically with testosterone. The mechanism by
which androgens act does not seem to involve an androgen
receptor. Oestrogen receptors were clearly shown to be
present in prostate cancer cells and so the mechanism
presumably involves activation of oestrogen receptor and
transforming growth factor beta, as growth can be blocked
by antibodies to this growth factor.
What emerges from this meeting is that oestrogens and
androgens have multiple effects on a variety of tissues, not
just those classically recognised and defined as 'target
tissues'. The brain, cardiovascular system, muscle, bone,
the immune system and many other tissues are apparently
influenced, albeit subtly in some cases, by sex steroids.
Equally striking is the emerging concept that hormones may
exert their effects not only by direct interaction with receptor
proteins, which then activate the appropriate biosynthetic
events, but also by modulating a large variety of intra- and
extracellular control mechanisms which, in turn, can control
the signalling mechanisms. We are only just starting to
discover the extent and complexity of this aspect of
hormone action.
VHT James
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Symposia, however well organised, are usually a mix of up-
to-date presentations describing novel and interesting results
and, at the other end of the scale, fairly boring accounts of
work already completed and out of date. This volume is an
account of the proceedings of that part of a joint symposium
between the German Cancer Centre and the EORTC devoted
to new approaches in drug design and, as expected, is a
curate's egg mix of interesting new data and material from
the ark. The first seven chapters make an interesting read and
deal with the design of new drugs using computational
chemistry and molecular modelling based on a knowledge of,
for example, the crystal structure ofreceptors. The chapter by
CW v d Leith and his colleagues sums up the state of the art
of this approach. Twelve years ago the expectations of
computer-supported drug design were enormously high but
'the fall was deep when it was recognised that computational
methods alone cannot predict reliable new lead structures'.
T1his is true, of course, but with the introduction of
combinatorial chemistry, for example, and user-friendly
computer programs to study receptor-drug interactions at
the atomic level one can predict that this will be an important
future approach. Indeed, drugs are already in the clinic that
have been uncovered by these methods and, should they
prove to be superior to analogues discovered by screening or
biochemical approaches, then one would expect programs
dedicated to discovering agents acting on abnormal pathways
in cancer such as the work described on the active site of
protein kinase C or o6 methyltransferase to expand rapidly.
Apart from some interesting findings with suramin, the
middle of the book is disappointing in that it deals with
rather mundane approaches involving cisplatin and other
conventional anti-cancer agents and attempts to improve
their selectivity by the design of analogues, the use of
combinations or attempts to overcome resistance. The Cancer
Chemotherapy Annual deals with these approaches each year
and this volume adds nothing that is either new or exciting.
The book perks up towards the end with some interesting
presentations on the bisphosphonates, bioreductives, steroid
carriers of BCNU and new agents for BNCT (boron neutron
capture therapy), an old approach but one which is now
being reapplied clinically on the basis ofsound scientific data.
T Connors
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This is a comprehensive text that is clear and well written by
the contributors. Many of the chapters are written by the
editors and draw on their experience as well as being well
referenced.
The book is well organised and begins with an entertaining
historical account of breast cancer, tracing the origins of
treatment to the earliest records available.
The subsequent chapters then describe the basic sciences of
anatomy, physiology and pathology of the breast and serve
as a useful source of reference. The often confusing area of
benign breast disorders and the overlap with pathology is
then tackled and clarified in chapters 6 and 7, with a helpful
description of abnormalities of normal breast development
and involution (ANDI).
The text then describes the epidemiology and aetiology of
breast cancer in a clear and concise way. Chapter 10
describes the diagnosis of breast cancer and draws on the
author's (Donegan) own experience. The section is well
illustrated with line drawings demonstrating clear examina-
tion and surgical techniques. The following chapter (11)
similarly gives an account of imaging, again combining
experience with referenced data. The author (Moskowitz)
writes authoritatively, describing the development of imaging
techniques and screening. This section also describes
ultrasound needle localisation techniques as well as other